Ann: Patrys Reports Progress on Preclinical Programmes, page-4

(RTTNews.com) - Puma Biotechnology Inc. ( PBYI ) announced results from the Phase III clinical trial of PB272, or neratinib, after the close Tuesday. The trial demonstrated that treatment with neratinib resulted in a 33% improvement in disease free survival versus placebo for the primary endpoint of disease free survival in the treatment of patients with breast cancer

Read more: http://www.nasdaq.com/article/puma-...-on-phase-3-data-20140723-00579#ixzz38L6KPuma Biotechnology has gapped open dramatically higher Wednesday morning and is now up 164.97 at $224.00 on strong volume. The stock has surged to a new high

went up $174